Diverse IgG subclass responses to adeno-associated virus infection and vector administration - Wikidata - awgldk - TriplyDB

Diverse IgG subclass responses to adeno-associated virus infection and vector administration

Diverse IgG subclass responses to adeno-associated virus infection and vector administration

http://www.wikidata.org/entity/Q42667110

about

A Temporal Model of Human IgE and IgG Antibody Function Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1 Progress and prospects: immune responses to viral vectors Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound AAV's anatomy: roadmap for optimizing vectors for translational success The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques Immunization delivered by lentiviral vectors for cancer and infectious diseases.AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8.Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.Gene Therapy for Duchenne muscular dystrophy.Generation and Characterization of Mouse Hybridomas Secreting Monoclonal Antibodies Specific for Human IgG3 Immune responses to AAV vectors: overcoming barriers to successful gene therapy Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy Humoral Immune Response to AAV.Integration-deficient lentiviral vectors: a slow coming of age.The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives.Unraveling the complex story of immune responses to AAV vectors trial after trial.Cell-Based Measurement of Neutralizing Antibodies Against Adeno-Associated Virus (AAV).Measuring immune responses to recombinant AAV gene transfer.Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model.Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.

P2860

Q21131207-E42911A4-18E4-447F-8875-AC6480857AA2 Q24634560-13F220D5-0428-4EF0-A47B-503E88D0FE0D Q28264531-0AA93F2E-41F6-4088-901B-EF60A3AD052B Q30447740-7538E66C-2A7F-4148-9AFA-F85AAAE5FEBB Q33659389-C979E27F-5C64-4234-B370-F94A99D6CB52 Q33730459-832D9577-9095-423A-9B03-F9B1B7483B09 Q34539879-AD41B1E0-5324-452F-B748-BC737E5300C8 Q35153203-7D906FEC-1F96-4D08-8DF8-D17F667FF0AF Q35568505-69316EC2-CAA1-41E1-9B56-D5632549844B Q35665240-D22AF426-F50B-4F1D-A5D3-EE12CD72ED8E Q35960506-A835968A-F03F-4696-A259-2A97CEB1D100 Q36171820-4025AEF2-B006-4E96-9F9E-25DF36D41846 Q36295934-C0C913FA-53F4-479B-912E-F17D9DDD593B Q36571195-DE8719FC-80F1-4793-AD5F-15B0D2BD76B8 Q36983740-F0442DFD-75BA-495D-B515-241F2A724D4D Q37066314-DE1CA8B2-A992-497A-B649-83E63609C7A0 Q37236099-488BCC70-C01A-4733-87B8-03FA080860DC Q37506025-0953509F-0E69-46DD-8915-930A30B6C377 Q39669977-67C79B6F-3B8A-4868-AD20-476AF7F1CF5F Q40073271-56398FF1-5E39-4B62-B697-9F873655A8F6 Q40445311-2B24FD0C-61D8-446E-ADD8-67FE06D2123F Q41363155-8825CA8D-C65A-4D3D-A1FB-A5C57CA645B0 Q41876346-FDE1CA49-D7FB-4998-8C89-6DB599E611BA Q54210526-4341A4CD-3C05-45F0-8CBD-B883D3233DE1

P2860

Diverse IgG subclass responses to adeno-associated virus infection and vector administration

http://www.wikidata.org/entity/Q42667110

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Diverse IgG subclass responses ...... tion and vector administration

@en

Diverse IgG subclass responses ...... tion and vector administration

@nl

type

label

Diverse IgG subclass responses ...... tion and vector administration

@en

Diverse IgG subclass responses ...... tion and vector administration

@nl

prefLabel

Diverse IgG subclass responses ...... tion and vector administration

@en

Diverse IgG subclass responses ...... tion and vector administration

@nl

P1433

Q42667110-5D539BCE-A9D4-4721-A16D-D05E26680047

P1476

Q42667110-13B4B0B1-753A-4D1A-BB69-57DA437BFAD0

P2093

Q42667110-0DCC5061-8E40-468B-96A1-492A7BC9FEB7

Q42667110-5BA06111-5662-4419-8493-C2E57C7E1B6E

Q42667110-7F3AD8B4-2A6D-4394-AC4F-9B11FDBC09FA

Q42667110-AA0D016A-AC94-4EB6-8C8E-E8C10DB7D3E6

Q42667110-D1CE69BE-AE4B-46A9-82A4-43682F4B4B43

Q42667110-D3D2D197-7B01-4B97-A50F-C07EE048F8D3

Q42667110-ED664FF9-3F39-4F39-B661-B3AE221A3FE7

P2860

Q42667110-26BEDBD8-5E83-4DF3-B203-1ABD2F271DB0

Q42667110-2DFCB0E9-CA86-4850-9422-7BF4D73BAD5F

Q42667110-35D56A41-CA61-42A3-8F57-A8118D5DD514

Q42667110-36957241-3D3D-4665-9337-06DC055CE629

Q42667110-3DB492C8-8F23-43D9-99F6-7AAA0DDF7F52

Q42667110-42BE1D7F-1AE0-4219-B83A-366F9B543429

Q42667110-4A85CBF2-129E-4E44-8A47-0BAB1ADC8FE8

Q42667110-4B18981C-68AF-43D3-BFFB-84B26890CCD2

Q42667110-6AAE3788-26FE-47F5-A2F9-6F2D5E75DAF6

Q42667110-7192A27C-CC5D-40C9-963C-16A860647C8E

P304

Q42667110-39267CB7-5414-4881-B980-AA66A9F98F0A

P31

Q42667110-9175E49A-2196-43E4-98D0-CB0FEF95D17F

P356

Q42667110-EA65E418-28BD-4EC7-86E3-A4FE3EC207C6

P433

Q42667110-882AB3E8-C4B0-4B83-92CF-24F30AFEC7EB

P478

Q42667110-79E0497F-8B33-4738-B165-8047769B9E08

P577

Q42667110-FC84C49B-9360-488C-BAA1-CC4F6AA7F0E9

P5875

Q42667110-C5F9FC76-A52A-4309-9BD0-86A8E85F1948

P698

Q42667110-6ADF68A6-4FA4-483D-BF38-2AACEC98C5E0

P921

Q42667110-777407B7-167B-4855-BDCC-34CD6F60C805

P932

Q42667110-074406C4-5E4C-4762-BA57-8A5D238C2231

P356

P1433

Journal of Medical Virology

P1476

Diverse IgG subclass responses ...... tion and vector administration

@en

P2093

Daniel J Hui

http://www.w3.org/2001/XMLSchema#string

Denise E Sabatino

http://www.w3.org/2001/XMLSchema#string

Federico Mingozzi

http://www.w3.org/2001/XMLSchema#string

Hojun Li

http://www.w3.org/2001/XMLSchema#string

Katherine A High

http://www.w3.org/2001/XMLSchema#string

Samuel L Murphy

http://www.w3.org/2001/XMLSchema#string

Shyrie A Edmonson

http://www.w3.org/2001/XMLSchema#string

P2860

Human parvovirus B19.

Prolonged activation of virus-specific CD8+T cells after acute B19 infection.

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

Immune responses to adenovirus and adeno-associated virus in humans.

Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection.

Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans

Molecular characterization of adeno-associated viruses infecting children

Characterization of adeno-associated virus genomes isolated from human tissues.

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates

P304

65-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMV.21360

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23495338

http://www.w3.org/2001/XMLSchema#string

P698

19031458

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

2782623

http://www.w3.org/2001/XMLSchema#string